1-N-Cbz-3-Hydroxyazetidine, 96.0%, 1g

4-Hydroxybenzylamine hydrobromide, 98.0%, 1g

4-Bromobenzyl-(4-chlorophenyl)ether, 97.0%, 1g

1-((Trifluoromethyl)thio)pyrrolidine-2,5-dione, 98%, 1g

Palmitoleic acid, 98.0%, 1g

3-Pyrrolidin-1-yl-benzoic acid, 95.0%, 1g

N-(2-(2-(2-(2-Aminoethoxy)ethoxy)ethoxy)ethyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide, 95+%, 50mg

GC capillary column ROTI®Cap-5 MS Ultra, 25 m, 0.32 mm, 1.00 µm, 1 Piece(s)

4-(2-Pyridyl)benzaldehyde>95.0%(GC)(T)5g

5-{[(2-chlorophenyl)methyl]sulfanyl}-4H-1,2,4-triazol-3-amine, 97%, 10mg

5,6,7,8-Tetrahydroquinazoline-2,4-diamine, 500mg

2-(Benzyloxy)-5-bromopyrimidine, 95.0%, 5g

7-METHOXY-1-METHYL-2-TETRALONE, 95.0%, 25g